ReviewAmerican journal of preventive cardiology2024
Unique features of dyslipidemia in women across a lifetime and a tailored approach to management.
Review in American journal of preventive cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE).Journal of endocrinological investigation · 2026Review
- Coronary Artery Disease in Women: Sex-Specific Pathophysiology, Risk Factors, Clinical Presentation and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Epidemiology and determinants of dyslipidemia in Iranian population: Results from the PERSIAN cohort.PloS one · 2026Article
- Gender Differences in Major Risk Factors for Cardiovascular Disease in Mexican Adults.Global heart · 2026Article
- Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- Prevalence, correlates of dyslipidaemia, and 10-year cardiovascular risk among people living with HIV and people without HIV adults in Rwanda: insights from the NCOHIRWA cohort study.Lipids in health and disease · 2025Article
- Gender disparities in coronary artery disease: a review of factors influencing clinical outcomes.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2025Review
- Position Statement on Cardiometabolic Health Across the Woman's Life Course - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Sex differences in hypercholesterolemia management (2002-2022): evidence from the Swiss National Health Surveys.Preventive medicine reports · 2025Article
- Leukocyte-Based Inflammatory Profiles Across Dyslipidemia Phenotypes: Patterns of Eosinophil-Related Indices.Medicina (Kaunas, Lithuania) · 2025Article
- Impact of Sex Differences on Lipids and Statin Utilization.Current atherosclerosis reports · 2025Review
- Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: Insights from the multicentre statin intolerance registry.American journal of preventive cardiology · 2025Article
- A strategy to increase identification of patients with Familial Hypercholesterolemia: Application of the Simon Broome lipid criteria in a large-scale retrospective analysis.American journal of preventive cardiology · 2025Article
- Eliminating Sex Disparities in Dyslipidaemia Screening, Diagnosis and Treatment.Heart international · 2025Review
- Chitosan-Based Nanoparticles Targeted Delivery System: In Treatment Approach for Dyslipidemia.International journal of nanomedicine · 2025Review
- Position Statement on Cardiometabolic Health Across the Woman's Life Course - 2025.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025Article
- Lipoprotein(a) throughout life in women.American journal of preventive cardiology · 2024Review
- Dyslipidemia in Pregnancy: A Systematic Review of Molecular Alterations and Clinical Implications.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of Review: Cardiovascular disease is a leading cause of death worldwide. Dyslipidemia is a critical modifiable risk factor for the prevention of cardiovascular disease. Dyslipidemia affects a large population of women and is especially pervasive within racial/ethnic minorities. Recent Findings: Dyslipidemia in pregnancy leads to worse outcomes for patients and creates increased cardiovascular risk for women at an older age. However, women remain underscreened and undertreated compared to men. Females also comprise a small portion of clinical trial participants for lipid lowering agents with increased disease prevalence compared to trial representation. However, recent lipid trials have shown different efficacies of therapies such as ezetimibe, inclisiran, and bempedoic acid with a greater relative benefit for women. Summary: Pathophysiology of dyslipidemia varies between men and women and across a woman's lifetime. While increased lipid levels or lipid imbalances are more common in postmenopausal women over age 50, conditions such as PCOS and FH produce higher cardiovascular risk for young women.Best practices for management of women with dyslipidemia include early screening with lifestyle intervention and pharmacotherapy with statin and non-statin agents to achieve guideline directed LDL-C thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.